Introduction
Balloon angioplasty is a well established therapeutic intervention for stenotic lesions of coronary arteries. 1 However, restenosis occurs in as many as 30-50% of patients after angioplasty because of formation of a thick intimal layer (neointima). Considerable efforts have been made in developing a therapeutic strategy for effectively suppressing smooth muscle cell (SMC) accumulation in the intima, which include administration of antibodies 2, 3 or antagonists 4, 5 against growth factors and antisense oligonucleotides [6] [7] [8] directed to transcription factors and cellcycle regulatory molecules required for cell proliferation. More recent studies demonstrated that adenovirus-or retrovirus-mediated transfer of a therapeutic gene into the vascular wall could be a promising treatment strategy. For example, it was reported that considerable inhibition of intimal hyperplasia was obtained by administration of an adenovirus containing the herpes simplex virus thymidine kinase gene together with the prodrug ganciclovir, 9, 10 an adenovirus containing the gene of the thrombin inhibitor hirudin, 11 and adenoviruses containing the genes of growth inhibitors for SMCs. [12] [13] [14] A variety of growth factors acting through tyrosine kinase-type receptors, which include platelet-derived growth factors (PDGFs), fibroblast growth factors (FGFs), epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I), have been implicated in formation of the neointima. [15] [16] [17] [18] PDGFs comprise homo-or hetero-dimers of two polypeptides, A and B. 19 The receptors for PDGFs consist of ␣-and ␤-isoforms. 19 The ␣-receptor binds either PDGF A-chain or B-chain, and the ␤-receptor binds only B-chain. As compared with PDGF A-chain PDGF B-chain is generally more potent as a mitogen and chemoattractant for SMCs. 20 In situ hybridization analysis revealed that mRNA of PDGF ␤-receptor is expressed at high levels in the neointima. 21 A recent study 22 demonstrated that PDGF-B chain transcript is detected in the luminal side of the neointima, suggesting that PDGF-B synthesized in the neointima may be involved in intimal hyperplasia via a paracrine or autocrine mechanism. In a rat carotid balloon injury model, neointima formation is completed at approximately 14 days after injury. 16 Ferns et al 2 demon-957 strated that daily infusion of neutralizing anti-PDGF antibody into athymic rats during the first 7 days following balloon injury caused a 40% reduction in the intimal lesion size in arteries of 8 days. We have recently observed that especially during the second week, tyrosine phosphorylation levels of both PDGF ␣-and ␤-receptors were markedly increased in injured rat carotid arteries, indicating that PDGF receptors are indeed activated in injured arteries. 23 Thus, the attempt to target PDGF by a gene transfer technique sounds promising, however, so far there has been no such report in the gene therapy of vascular proliferative disease.
Here we report a study that establishes the role for the B chain of PDGF in the pathogenesis of neointima formation during the second week, by using an adenovirusmediated gene transfer technique. We constructed a replication-deficient adenoviral vector containing the gene encoding the extracellular region of PDGF ␤-receptor (PDGFXR). The soluble PDGFXR protein was previously shown to have the ability to bind PDGF-BB, but not PDGF-AA, with high affinity and to function as a selective antagonist for PDGF-B chain, blocking the biological activity of PDGF-B. 24 We examined whether adenovirusmediated transfer of the PDGFXR gene into injured vascular wall blocked PDGF-B actions and reduced neointima formation in a rat carotid model.
Results
In vitro expression of PDGFXR Primary cultures of rat aortic smooth muscle cells (SMCs) were infected with either an adenovirus containing the gene encoding the extracellular region of human PDGF ␤-receptor (AxCAPDGFXR) or a control adenovirus containing the Escherichia coli lacZ gene (AxCALacZ). Three days later, the expression of PDGFXR was examined by reverse transcription-polymerase chain reaction (RT-PCR) analysis of RNA from cells and also by Western blot analysis of conditioned media employing a specific antibody recognizing the extracellular domain of PDGF ␤-receptor. The primer set used for RT-PCR was specific for PDGFXRmRNA, since one primer was derived from the vector sequence. PDGFXR mRNA was detected in AxCAPDGFXR-infected, but not AxCALacZ-infected SMCs, whereas ␤-actin mRNA was detected similarly in cells infected with either adenovirus (Figure 1a) . PDGFXR cDNA was not amplified from these RNA samples by PCR without RT. Western blot analysis readily detected PDGFXR protein with the molecular mass of approximately 110 kDa in the conditioned media from AxCAPDGFXR-infected SMCs, but not from AxCALacZinfected SMCs (Figure 1b) . The apparent molecular mass of PDGFXR is consistent with a previously reported value, 24 and is larger than the predicted molecular mass (60 kDa). A previous study 24 showed that the difference in molecular mass was because of its glycosylation. PDGFXR protein was not present in detectable amounts within cells. Thus, infection of cultured SMCs with AxCAPDGFXR causes the production of PDGFXR protein, and substantial amounts of PDGFXR protein are secreted into the extracellular space. We studied timedependent changes in the amount of PDGFXR protein released from AxCAPDGFXR-infected SMCs. Secretion of PDGFXR protein was detected in medium at 1 day after We next examined the capacity of PDGFXR protein to inhibit PDGF-BB-induced cellular responses. PDGF-BB increased the extent of PDGF ␤-receptor tyrosine phosphorylation in cultured SMCs (Figure 2b ). The addition of recombinant PDGFXR abolished PDGF-BB-induced stimulation of PDGF-␤-receptor tyrosine phosphorylation. Consistent with this, PDGFXR nearly completely inhibited PDGF-BB-induced DNA synthesis in cultured SMCs (Figure 2c ).
Gene transfer into injured arterial wall
Guzman et al 25 reported that the efficacy of adenovirusmediated gene transfer into rat balloon-injured carotid artery is markedly improved when an adenovirus is introduced into arteries 5-7 days after injury compared with administration immediately after injury. We confirmed their observation by comparing the transfection efficiency between injured arteries exposed to AxCALacZ immediately after (0 day) and 5 days after injury ( Figure  3a and b). Thus, in arteries exposed to AxCALacZ 5 days after injury, lacZ expression was found in Ͼ90% of neointimal cells with scattered medial SMCs only in the most inner layer being transduced, whereas in arteries infected at 0 day only an occasional expression of lacZ was found in medial SMCs (Figure 3a and b) . In addition, we tested the effects of several titers (1 × 10 8 to 1 × 10 11 p.f.u./ml) of AxCALacZ with the delayed infection protocol. The percentages of X-gal-positive cells in the neointima was 2%, 32%, 92% and 85% (a mean of two or three vessels) at 1 × 10 8 , 1 × 10 9 , 1 × 10 10 and 1 × 10 11 p.f.u./ml of AxCALacZ, respectively. Thus, 1 × 10 10 p.f.u./ml of the adenovirus conferred the optimal expression of lacZ. By employing the same infection protocol, we evaluated by RT-PCR analysis, the expression of PDGFXR in injured arteries that underwent infection with an adenovirus. As shown in Figure 1a , PDGFXR mRNA was detected in AxCAPDGFXR-infected, but not in AxCALacZ-infected arteries, while ␤-actin mRNA was detected equally in arteries infected with either adenovirus.
Effects of PDGFXR expression on neointima formation, PDGF receptor activation and bromodeoxyuridine labeling of cells We introduced either AxCAPDGFXR, AxCALacZ or AxCA containing no foreign gene of 1 × 10 10 p.f.u./ml into injured left common carotid arteries 5 days after balloon injury. A fourth set of injured arteries was treated with vehicle alone. Fourteen days after balloon injury, we measured the areas of the intima and the media in arteries and determined intimal to medial area (I:M) ratio. The administration of AxCAPDGFXR substantially reduced neointima formation as compared with the administration of vehicle alone ( Figure 4 ). In contrast, the administration of AxCALacZ or AxCA did not inhibit neointima formation. Quantitatively, the intimal area in the AxCAPDGFXR group was 57% reduced as compared with the AxCALacZ group. The medial area was similar among the four treatment groups. As a result the I:M area ratio was considerably reduced in the AxCAPDGFXR group as compared with the vehicle group, the AxCALacZ group or the AxCA group ( Figure 5 ).
-PDGF-BB to PDGFXR protein (a), and inhibition by PDGFXR protein of PDGF-BB-induced PDGF ␤-receptor tyrosine phosphorylation (b) and DNA synthesis (VC) in SMCs. A, recombinant PDGFXR protein was immobilized on to 48-well plates. Binding of 125 I-PDGF-BB to PDGFXR was determined in the presence of various concentrations of unlabeled PDGF-BB, PDGF-AA or EGF. Each value is a mean ± s.e. of three determinations. (b) SMCs
We next examined whether PDGFXR expression inhibited PDGF ␤-receptor tyrosine phosphorylation in injured arteries. Tyrosine phosphorylation levels of PDGF ␤-receptor (the mean value of three determinations from two independent experiments) were four-fold increased in AxCALacZ-infected injured arteries (P = 0.02), as compared with non-injured arteries (Figure 6a , upper panel), consistent with our previous observation. 23 However, tyrosine phosphorylation levels of PDGF ␤-receptor in AxCAPDGFXR-infected injured arteries were not different from levels in non-injured arteries. Western blot using anti-PDGF ␤-receptor antibody to recognize the cytoplasmic domain of PDGF ␤-receptor showed that the protein level of 180 kDa PDGF ␤-receptor was similar among the non-injured, AxCALacZ-infected injured and AxCAPDGFXR-infected injured arteries (Figure 6a , lower panel). We also examined the effects of PDGFXR expression on tyrosine phosphorylation of PDGF ␣-receptor and EGF receptor. Tyrosine phosphorylation of PDGF ␣-receptor (the mean of two determinations) in AxCALacZ-infected injured arteries was three-fold increased, as compared with non-injured arteries (Figure 6b ), consistent with our previous observations. 23 Tyrosine phosphorylation levels of PDGF ␣-receptor in AxCAPDGFXRinfected injured arteries were similar to levels in noninjured arteries (Figure 6b ). Tyrosine phosphorylation of EGF receptor in AxCALacZ-infected injured arteries was similar to that of non-injured arteries (Figure 6c ). The expression of PDGFXR did not affect tyrosine phosphorylation of EGF receptor (Figure 6c) . Thus, the expression of PDGFXR blocked tyrosine phosphorylation of both ␣-and ␤-receptors of PDGF, but did not affect tyrosine phosphorylation of EGF receptor, in injured arteries.
Finally, we examined whether the expression of PDGFXR inhibited SMC proliferation in vivo in injured arteries. As shown in Figure 7 , the expression of PDGFXR reduced the percentage of BrdU-positive cells in the intima at 10 days by approximately 60%. The expression of PDGFXR also tended to decrease the percentage of BrdU-positive cells in the media.
Discussion
In the present study we attempted to determine the effect of the local expression of the PDGF-B chain antagonist PDGFXR on neointima formation after arterial injury with an efficient, adenovirus-mediated gene transfer technique. The efficient blockade of PDGF-B activity by the local expression of PDGFXR was obtained as demonstrated by the suppression of tyrosine phosphorylation of PDGF ␣-and ␤-receptors in injured arteries ( Figure 6 ). This was accompanied by a substantial inhibition of neointima formation and proliferation of SMCs in injured arteries ( Figures 4, 5 and 7) . Thus, the present results indicate that PDGFXR protein acts as an effective antagonist for PDGF-B chain in vivo, and provide further support for the critical role of PDGF-B chain in neointima formation.
A previous report demonstrated that blockade of PDGF action by repeated intraperitoneal injections of anti-PDGF antibody for the first week resulted in a reduction in the area of the neointima in injured rat carotid at 8 days after injury. 2 The anti-PDGF antibody employed in the study did not clearly discriminate PDGF isoforms. 2 In the present study, we explored the effect of the selective blockade of PDGF-B chain action by PDGFXR, which scavenges only B-chain of PDGF ( Figure  2 ). The suppressing effects of PDGFXR on PDGF receptor tyrosine phosphorylation and neointima formation ( Figures 5-7) indicate the importance of PDGF-B chain. In addition, the expression of PDGFXR inhibited tyrosine phosphorylation of both ␣-and ␤-receptors in injured artery ( Figure 6 ). These results suggest that PDGF-B chain is largely responsible for the activation of PDGF ␣-receptor as welll as PDGF ␤-receptors in injured vessels (Figure 6 ), although both A-chain and B-chain of PDGF can activate PDGF ␣-receptor. Sirois et al 26 recently reported that down-regulation of PDGF ␤-receptor expression in injured artery by local administration of antisense oligonucleotides suppressed neointima formation. Although the roles of PDGF ␣-receptor and PDGF-A chain in neointima formation, both of which are expressed in blood vessels, still remain elusive, our results together with the results of Sirois et al 26 indicate that PDGF ␤-receptors and PDGF-B chain are critically important for neointima formation.
PDGF-B chain is a well known potent in vitro mitogen and chemoattractant for SMCs. 20 The anti-PDGF antibody infusion study 2 revealed that the 3 H thymidine labeling of the neointimal and medial cells in the anti-PDGF group was not reduced at 8 days compared with the corresponding values in the control group, implying that in the first week the inhibition of neointima formation by administration of anti-PDGF antibody is due primarily to interference with PDGF-induced chemotactic migration of medial SMCs into the intima. In contrast, the present study focused upon examining the effects of blocking PDGF-B chain action mainly during the second week,
Figure 4 Representative cross-sections of (a) a non-injured artery, (b) an injured artery without exposure to a virus, (c) an injured artery exposed to AxCALacZ, (d) an injured artery exposed to AxCA and (e) an injured artery exposed to AxCAPDGFXR. Injured arteries were harvested 14 days after injury, and histologic sections were stained with Elastica van Gieson staining. The original magnification was × 30.
since injured arteries were infected with adenoviruses at 5 days. The BrdU labeling of the neointimal cells in the PDGFXR group at 10 days was approximately 60% reduced compared with the value in the lacZ group, implying that PDGF-B chain substantially contributes to SMC proliferation in injured arteries during the second week. The results in our study do not exclude that PDGF-B chain also acts as a chemoattractant in the second week. These observations suggest that the role of PDGF in proliferation of SMCs may be different, depending on the timing after injury.
Recent studies demonstrated higher efficacy of adenovirus-mediated gene transfer into the vascular wall as compared with liposome-or retrovirus-mediated gene transfer. 25, 27, 28 However, some studies showed that adenovirus-mediated gene transfer immediately after vascular injury did not confer a satisfactorily high efficiency. 25, 29 In the present study, we observed that delayed exposure of vessels to an adenovirus at 5 days markedly facilitated gene transfer into cells of the vascular wall, confirming the report by Guzman et al. 25 Even using the protocol of delayed administration of an adenovirus, gene expression is confined almost exclusively to neointimal SMCs with medial SMCs minimally transduced ( Figure  2 ), which is also consistent with a previous report. 25 In gene transfer to target PDGF-B, however, this selectivity does not appear to be a drawback, because both transcripts of PDGF B and PDGF ␤-receptor are largely detected in the neointima of injured arteries. 21, 22 In agreement with this, the present study showed that proliferation of the neointimal SMCs was more strongly suppressed than that of the medial SMCs (Figure 7) .
The present study is the first to show that local expression in blood vessels of an extracellular domain of a receptor tyrosine kinase effectively blocks the action of the growth factor. The present approach may be more promising than other gene therapy approaches that have been reported to inhibit neointima formation in the rat for the following reasons: first, PDGF-B chain likely plays a role of greater importance in neointima formation of at 961
Figure 5 Local expression of PDGFXR inhibits neointima formation. Intimal and medial areas were measured on histologic cross-sections of arteries obtained 14 days after injury and intimal-to-medial (I/M) area ratio was calculated. Injured rat carotid arteries were treated with either vehicle alone (no virus), AxCALacZ, AxCA or AxCAPDGFXR 5 days after injury. Each value is a mean ± s.e. of the data from nine to 11 arteries, except the AxCA group in which the number of arteries was three n.s. denotes statistically no significant difference.

Figure 6 Local expression of PDGFXR inhibits tyrosine phosphorylation of PDGF ␤-receptor and PDGF ␣-receptor, but not of EGF receptor. (a) Anti-phosphotyrosine (PY) and anti-PDGF ␤-receptor Western blots of anti-PDGF ␤-receptor immunoprecipitates. (b) Anti-PY Western blots of anti-PDGF ␣-receptor immunoprecipitates. (c) Anti-PY Western blots of anti-EGF receptor immunoprecipitates. Arrowheads denote the position of respective receptors. Receptors were immunoprecipitated by using respective specific antibodies from homogenates of non-injured arteries and injured arteries at 14 days exposed to either AxCALacZ or AxCAPDGFXR, separated on a SDS-8% polyacrylamide gel and analyzed by Western blotting as described in Materials and methods. The bands on Western blots were quantified by a densitometer as described in Materials and methods and expressed as fold over the basal level in non-injured arteries.
Figure 7 Local expression of PDGFXR inhibits bromodeoxyuridine labeling of SMCs in the intima and media. BrdU-positive cells in the intima and media of injured carotid arteries at 10 days exposed to either AxCALacZ or AxCAPDGFXR were determined by immunohistochemistry employing anti-BrdU antibody as described in Materials and methods. Each value is a mean ± s.e. of the data from three arteries.
least the rat carotid model than other growth factors such as EGF and IGF-I, as suggested by our observation that tyrosine phosphorylation of PDGF receptors, but not of EGF receptor or insulin receptor substrate-1, 23 was increased in injured arteries. Second, different to other therapeutic gene products such as dominant negative RAS and p27 kip1 , PDGFXR is a secreted and diffusible protein, which affects neighboring nontransfected cells, thereby amplifying the action preventing neointima formation; thus, the bystander effect can be expected in the case of PDGFXR. Finally, PDGF-B chain possesses both mitogenic and chemotactic activities. 17, 20 Therefore, blockade of the PDGF-B chain action is expected to result in inhibition of both proliferation and migration of SMCs, leading to more effective suppression of neointima formation.
The expression of PDGFXR caused a 57% inhibition of neointimal formation in the face of nearly complete suppression of increased tyrosine phosphorylation of PDGF␣-and ␤-receptors (Figures 5 and 6 ). Besides PDGFs, the involvement of several other growth factors is demonstrated in the rat carotid model. For example, blockade of the action of either angiotensin II 4,30,31 or thrombin 11 has been shown to result in inhibition of neointima formation similar to or greater than the inhibition in the present study. In the case of angiotensin II, it may act through the PDGF system, because we previously observed that blocking angiotensin II action led to inhibition of activation of PDGF ␣-and ␤-receptors in injured arteries. 23 In terms of this, we recently found that angiotensin II stimulated the gene expression of PDGF-B chain in vitro in neointimal SMCs (Deguchi and Takuwa, unpublished observation). Thrombin is demonstrated to stimulate PDGF-B production in endothelial cells, raising the possibility that thrombin may also act through the PDGF-B chain. Thus, it is possible that these vasoactive peptides may act at least in part through PDGF in vivo, which may account for greater inhibition of neointima formation when the actions of peptides are blocked.
The present study was performed in the rat carotid model which is much more simplistic than human lesions, and in which, besides SMC proliferation, there is a contribution of proliferation of other cell types, matrix secretion and thrombus formation. 15, 16 It is presently unknown how effective for human atherosclerotic lesions the blockade of PDGF-B action is. It is also not known how to achieve sufficient efficiency of transgene expression in vivo in human diseased arteries. It might be worth trying delayed exposure to an adenovirus in human atherosclerotic arteries, although technical problems associated with a recatheterization only several days after the initial angioplasty and manipulation for gene transduction must be solved.
Materials and methods
Construction of PDGFXR cDNA and adenovirus vector
We constructed a recombinant replication-deficient adenovirus (AxCAPDGFXR) containing the cDNA of the extracellular region (corresponding to amino acids 1-531) of human PDGF ␤-receptor (PDGFXR) downstream of the CAG promoter that consists of the cytomegalovirus 1E enhancer and chicken ␤-actin promoter. The 1.8-kb cDNA encoding PDGFXR with a stop codon TAG incorporated at 3Ј end was obtained by PCR using phPDGF-R (a gift from Dr H Okazaki, Kirin Brewery, Yokohama, Japan) as a template, and was cloned into a pCAGGSderived expression vector pCAcc between the EcoRI and BglII sites. 32 Then, the 4.2-kb cassette containing the CAG promoter and PDGFXR cDNA was excised with ClaI, made blunt-ended and ligated into a cosmid pAx1cw at the ClaI site. 33 The resulting cosmid, pAx1hPDGFXR, was cotransfected into 293 cells with EcoT221-cut adenovirus DNA-terminal peptide complex (TPC) from the E3 deletion mutant Ad5dlx. 34 Single viral clones were isolated by limiting dilution, and screened for PDGFXR cDNA. A single positive clone was amplified in 293 cells and subsequently purified on cesium gradients. Viral stocks of 1 × 10 11 p.f.u./ml of AxCAPDGFXR, AxCA (a control vector containing no foreign gene), and AxCALacZ (a control vector containing the Escherichia coli lacZ gene) were prepared as described.
In vitro gene transfer Rat SMCs were obtained by an explant method 36 and maintained in Dulbecco's modified Eagle's minimal essential medium (DMEM) supplemented with 10% fetal calf serum, 10 5 units/l penicillin G and 137 mol/l streptomycin under the atmosphere of 95% air plus 5% CO 2 at 37°C. Cells on a 35-mm diameter dish were grown to confluency and infected with an adenovirus by incubation for 1 h in 300 l of medium containing 3 × 10 7 p.f.u./ml, which was equivalent to approximately 10 p.f.u. of adenovirus per cell. Three days later, media and cells were analyzed for the expression of a protein and a gene by Western blot analysis and reverse transcriptionpolymerase chain reaction (RT-PCR), respectively. For determination of the time-course of PDGFXR protein secretion in AxCAPDGFXR-infected cells, cells were replaced with fresh serum-free DMEM 24 h before harvest of conditioned media. For Western blot analysis, collected media were acid-precipitated with a final concentration of 10% of trichloroacetic acid. Precipitates from media, and cells were solubilized in Laemmli's sodium dodecylsulfate (SDS)-sample buffer, and amounts corresponding to half of the media and 10% of the cells were separated on a SDS-10% polyacrylamide gel and transferred on to an Immobilon P membrane (Millipore, Tokyo, Japan). The membrane was probed with sheep polyclonal anti-human PDGF ␤-receptor antibody raised against a synthetic peptide corresponding to amino acid 100-117 of human PDGF ␤-receptor sequence (OA-11-755, Cambridge Research Biochemicals, Cheshire, UK). The density of the PDGFXR band was quantified by densitometry using a scanning densitometer (PDI). The amount of PDGFXR protein was estimated by comparing the density of each sample with that of the standard PDGFXR purified from PDGFXR-producing CHO-K1 cells. Concentration of purified PDGFXR was estimated by silver staining of SDS-PAGE. The results were expressed as per cent of maximum density value (OD). For RT-PCR analysis, total RNA (0.8 g) isolated from SMCs was used as template to synthesize cDNA using Superscript II reverse transcriptase (GIBCO-BRL, Rockville, MD, USA). One-twentieth of the RT product was amplified by PCR using a sense primer to the human PDGF ␤-receptor sequence 1368 to 1391 when 'A' of the initiation codon 'ATG' is numbered as 1 (CCTCAAAAGGTGTCCACGTGAGCT) and an antisense primer to the vector sequence (GGGCTTCATGA TGTCCCCATAA). RNA samples were also subjected to PCR without RT. The PCR using this primer pair is expected to amplify a 281-bp DNA containing 235-bp of human PDGF ␤-receptor sequence and 46-bp of vector sequence. Endogenous rat PDGF ␤-receptor cDNA cannot be amplified by the primer pair. PCR comprised 20 cycles of 0.5 min at 94°C, 0.5 min at 55°C and 1 min at 72°C with an initial denaturation of 1 min at 94°C. To ensure the integrity of total RNA, each product of the RT reaction was also amplified for ␤-actin cDNA by using sense and antisense primers (ATCATGTTTGAGACC TTCAACAC and AGCCACGCTCGGTCAGGATCTT CATG, respectively) that span the 228-bp sequence of exon 4.
In vivo gene transfer Deendothelializing vascular injury was achieved in the rat left common carotid artery as previously described. 7, 23, 31 The injured common carotid artery was exposed to adenovirus either immediately after balloon injury (at 0 day) or 5 days after injury. Adenovirus infection at day 0 was carried out as follows. With a re-clamp in the proximal portion of the common carotid, 80 l of DMEM containing an adenovirus or DMEM alone was infused through the external carotid into the common carotid artery using a 24-gauge catheter. After 40 min, the viral solution was withdrawn, the arteriotomy was closed by suture using 10-0 nylon under a microscope, and the common carotid was reperfused. For adenovirus infection at 5 days, animals were reanesthetized and the common carotid and its external and internal branches were exposed through the previous incision. An arteriotomy was made in the same portion of the external carotid artery as the primary operation. A solution containing AxCAPDGFXR, AxCA or AxLacZ, or DMEM alone was delivered into the common carotid as described above.
Gene transfer was assessed 3 days after exposure to an adenovirus. The carotid artery was removed, cut longitudinally to expose the lumen and subjected to Xgal (5-bromo-4-chloro-3-indolyl-␤-d(-)-galactopyranoside) staining solution.
14 To estimate gene transfer efficiency in histological sections, neointimal cells were counted in three high power (× 400) fields of transduced arteries, and the percentage of X-gal-positive cells was calculated.
The expression of PDGFXR gene was examined by the isolation of total RNA from carotid arteries and subsequent RT-PCR analysis of PDGFXR transcript as described in the 'In vitro gene transfer' section in Methods.
Morphometric analysis of carotid arteries 7, 23, 31 and bromodeoxyuridine (BrdU) labeling experiments 38 were performed as described.
Binding of 125
I-PDGF-BB to PDGFXR and in vitro effects of PDGFXR on PDGF-B-induced cellular responses The PDGFXR cDNA was expressed in CHO-K1 cells. CHO-K1 cells were cotransfected with the PDGFXR expression plasmid pCAGGS-XR and the neomycinresistant gene expression plasmid pKM3 (donated by Dr H Nojima, Osaka University, Japan) by LipofectoAMINE reagent (GIBCO-BRL) and after 72 h were selected with G418 (0.6 mg/ml). Colonies were screened by analyzing the conditioned media with Western blotting using anti-PDGF ␤-receptor antibody recognizing the extracellular region of the receptor (OA-11-755). Conditioned media from PDGFXR-producing CHO-K1 cells were purified by wheat germ agglutinin (WGA) Sepharose 6MB (Sigma, St Louis, MO, USA) and immobilized by adsorption on to a plastic surface of a 48-well plate as described.
24 125 I-PDGF-BB binding experiment was performed as described previously. 24 PDGFXR protein was also produced in Sf9 insect cells. Briefly, the PDGFXR cDNA was ligated into pVL1393 at the EcoRI site downstream of the polyhedrin promoter to create pVL1393-XR. Sf9 cells were cotransfected with pVL1393-XR and Baculogold baculovirus DNA (PharMingen, San Diego, CA, USA), and the recombinant baculovirus encoding the PDGFXR cDNA was recovered. 39 PDGFXR protein in serum-free conditioned medium of Sf9 cells infected with the baculovirus carrying the PDGFXR cDNA was purified by WGA Sepharose 6MB column as described above. SMCs made quiescent by serum deprivation were stimulated with PDGF-BB alone or PDGF-BB plus PDGFXR, and analyzed for tyrosine phosphorylation of PDGF ␤-receptors as described below and 3 H thymidine incorporation into DNA as described previously. 40 Analysis of tyrosyl phosphorylation of PDGF receptors and EGF receptor and protein contents of PDGF ␤-receptor Segments exposed to an adenovirus of left injured common carotid artery at 14 days after injury and left noninjured common carotid artery from rats that underwent sham operation were analyzed for tyrosyl phosphorylation and protein content of PDGF receptors as described previously. 23, 37 For immunoprecipitation, specific rabbit polyclonal anti-PDGF ␣-receptor antibody raised against the carboxyl-terminal 110 amino acids of mouse PDGF ␣-receptor fused to glutathione S-transferase expressed bacterially (Seikagaku, Tokyo, Japan), specific rabbit polyclonal anti-PDGF ␤-receptor antibody raised against the peptide (1013-1025) of human PDGF ␤-receptor (UBI, Lake Placid, NY, USA), sheep polyclonal anti-epidermal growth factor (EGF) receptor antibody against the protein encoded by exons 15-18 of human EGF receptor gene fused to glutathione S-transferase (UBI), were employed. The density of the bands on Western blots was quantified by densitometry using a scanning densitometer (PDI). The results were expressed as fold increase over the basal value in non-injured carotid artery.
Statistical analysis
Comparisons of differences between two groups were analyzed by Student's t test. Multiple comparisons of differences between groups were analyzed by Scheffe's test. 23 
